Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00041808
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2002-07-17
Brief Title:
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
Sponsor:
FeRx
Organization:
FeRx
Study Overview
Official Title:
A Phase III Single Dose Trial to Determine The Safety Tolerance Pharmacokinetic Profile and Preliminary Activity of Intrahepatic Delivery Via Hepatic Artery Catheterization of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers MTC-DOX in Patients With Metastatic Cancer to the Liver
Status:
COMPLETED
Status Verified Date:
2003-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
MTC-DOX is Doxorubicin or DOX a chemotherapy drug that is adsorbed or made to stick to magnetic beads MTCs MTCs are tiny microscopic particles of iron and carbon When DOX is added to MTCs DOX attaches to the carbon part of the MTCs MTC-DOX is directed to and deposited in the area of a tumor where it is thought that it then leaks through the blood vessel walls Once in the surrounding tissues it is thought that Doxorubicin becomes free from the magnetic beads and will then be able to act against the tumor cells The iron component of the particle has magnetic properties making it possible to direct MTC-DOX to specific tumor sites in the liver by placing a magnet on the body surface It is hoped that MTC-DOX used with the magnet may target the chemotherapy drug directly to liver tumors and provide a treatment to patients with cancers that have spread to the liver
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None